|
Randomized
placebo-controlled evaluation of hydrazine sulfate in patients with advanced
colorectal cancer
Loprinzi
CL, Kuross SA, O'Fallon JR, Gesme DH Jr, Gerstner JB, Rospond RM, Cobau CD,
Goldberg RM
Mayo
Clinic, Rochester, MN 55905
Purpose.
Hydrazine sulfate is a controversial agent that was originally studied in cancer
patients approximately 20 years ago.
Based on a series of recent trials that suggested that this drug might have
utility in cancer patients, we conducted this study.
Patients
and Methods. Patients with metastatic colorectal cancer were randomized to
receive hydrazine sulfate or placebo in a double-blinded manner.
Protocol patients did not concurrently receive any other systemic antineoplastic
treatment.
Results.
There were 127 assessable patients entered onto this clinical trial.
Data from the study showed trends both for poorer survival and for poorer
quality of life (QL) in the hydrazine group.
There were no significant differences in the two study arms with regard to
anorexia or weight loss.
Conclusion.
This trial failed to demonstrate any benefit for hydrazine sulfate.
PMID:
8201373 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8201373&dopt=Abstract
|
